Q2 EPS Estimate for Avadel Pharmaceuticals Lifted by Analyst

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Investment analysts at Lifesci Capital increased their Q2 2025 earnings estimates for Avadel Pharmaceuticals in a research note issued to investors on Thursday, June 5th. Lifesci Capital analyst M. Belghiti now expects that the company will post earnings of $0.05 per share for the quarter, up from their prior forecast of $0.02. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The firm had revenue of $52.51 million during the quarter, compared to analysts’ expectations of $50.57 million. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 93.34%. The company’s revenue for the quarter was up 93.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) earnings per share.

A number of other research firms also recently commented on AVDL. Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Avadel Pharmaceuticals in a research note on Tuesday, March 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $19.43.

Avadel Pharmaceuticals Stock Performance

Shares of Avadel Pharmaceuticals stock opened at $10.23 on Monday. The firm has a 50-day moving average of $8.63 and a 200-day moving average of $8.87. The stock has a market cap of $989.64 million, a PE ratio of -12.95 and a beta of 1.45. Avadel Pharmaceuticals has a 52-week low of $6.38 and a 52-week high of $17.30.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Exencial Wealth Advisors LLC bought a new position in shares of Avadel Pharmaceuticals in the first quarter worth about $82,000. Thoroughbred Financial Services LLC bought a new position in shares of Avadel Pharmaceuticals in the first quarter worth about $82,000. Kovack Advisors Inc. bought a new position in shares of Avadel Pharmaceuticals in the first quarter worth about $90,000. Quarry LP bought a new position in shares of Avadel Pharmaceuticals in the first quarter worth about $94,000. Finally, Pekin Hardy Strauss Inc. bought a new position in shares of Avadel Pharmaceuticals in the first quarter worth about $110,000. Institutional investors own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.